An Open-label, Randomized, Parallel-group Study to Assess the Pharmacokinetic Bioequivalence of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants
Latest Information Update: 18 Feb 2022
At a glance
- Drugs Guselkumab (Primary)
- Indications Crohn's disease; Erythrodermic psoriasis; Familial adenomatous polyposis; Giant cell arteritis; Hidradenitis suppurativa; Lupus nephritis; Palmoplantar pustulosis; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Pustular psoriasis; Systemic scleroderma; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
Most Recent Events
- 02 Feb 2022 Status changed from recruiting to completed.
- 05 Jul 2021 Planned End Date changed from 20 Sep 2021 to 30 Dec 2021.
- 18 Aug 2020 Planned End Date changed from 29 Jul 2020 to 20 Sep 2021.